Medicinal Cannabis Market report categorizes the Global report by product, and geography- Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Medicinal cannabis, also known as medicinal marijuana, is used either to treat disease or improve symptoms. Cannabis has been considered to be a major source of drug addiction. Extract from the dried flower bud part of the plant called as Marijuana has certain medicinal properties. The two cannabinoids - delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are being used in treatment of certain disease or health conditions such as pain, blood pressure, memory, concentration, appetite, sensory stimulus, muscular problems, and seizures.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/40

Medicinal Cannabis Market Dynamics

However, the debate still continues regarding the approval, safety and usage of cannabis (marijuana) for medicinal purpose, due to differences in the laws pertaining to this smoked drug. Hence, studies are conducted extensively to establish the safety aspect of this drug. Various states in the U.S. have already legalized cannabis (marijuana) for medicinal purposes. Scientific research of chemicals in the cannabis plant for its potential medicinal use has led to a shift in its demand purpose. Regulatory clearance has played a major role in the growth of medicinal cannabis market.

Other names of Cannabis - grass, pot, dope, Mary Jane, hooch, weed, hash, joints, brew, reefers, cones, smoke, mull, buddha, ganga, hydro, yarndi, heads, and green.

Request for an in-depth table of contents for this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/40

The U.S. FDA has approved two medications, Marinol and Syndros, which contain dronabinol in pill form. However, the FDA has not approved the marijuana plant as a medicine. The medicinal cannabis (marijuana) is administered in either of the ways – liquid extract, vaporized form, smoked or solid form.

Prevalent Scenario in the Medicinal Cannabis Market

According to the Medical Marijuana, Inc., the estimated size of the legal marijuana industry in the U.S. is US$ 7.1 billion in 2016. This is an increase of 25% Y-o-Y. As of 2016, 28 states in the U.S. have legalized marijuana for medicinal purpose with some more gearing up for votes on the recreational use of marijuana. California, Nevada, Maine, and Massachusetts states in November 2016, voted to legalize the medicinal use of marijuana. The accelerated pace of legalization of cannabis (marijuana) in the U.S. has attracted the attention of global investors in the medicinal cannabis market. However, lack of formulation of a comprehensive law pertaining to medicinal marijuana in some states inhibits patient access to the drug.

Important role of Regulatory Authorities in the Medicinal Cannabis Market Trend

According to the United Nations, marijuana was the most widely used drug globally in 2014, with around 183 million users. Such a large user base makes it highly lucrative taxable opportunity, which is influencing various governments worldwide to initiate studies regarding legalization of the drug for medicinal use. The National Institute on Drug Abuse is still conducting research on cannabis (marijuana) to treat numerous diseases and conditions such as autoimmune disease, pain, inflammation, seizures, mental disorders, and substance abuse disorders. Regulatory compliance is a key factor that influences cost, quality, and safety of cannabis (marijuana) medicines, as well as the capacity for the manufacturers in the medicinal cannabis market to be responsive, scalable, and innovative.

Additional Information on such Research Findings can be Availed At: https://www.coherentmarketinsights.com/ongoing-insight/medicinal-cannabis-market-40

Medicinal Cannabis Market Future Outlook

Potential medicinal cannabis markets other than the U.S., include Canada, Israel, Australia, and Spain. Mexico is also in process to consider the legalization of cannabis. Other countries are expected to consider legalization of the drug, once conclusive evidence regarding the safety and efficacy of cannabis are obtained through extensive research. According to Arcview Group—a cannabis industry investment and research firm—around 200 investors met companies to capitalize on lucrative opportunities from commercialization of medicinal cannabis. This implies that there is a huge potential in the medicinal cannabis market and pharmaceutical and biotechnology companies need to focus on increasing awareness about the drug emerging economies.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Synthetic Biology Market by various industry segment and provides information - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Synthetic biology is a combination of biology and biomedical engineering principles that favors designing and construction of novel biological parts & systems and also the reconstruction of preexisting designs according to specific application requirements. Synthetic biology is extensively used in the field of medical and pharmaceuticals to produce and manufacture improved biological drugs and systems to meet various challenges in the healthcare sector. Synthetic biology offers various opportunities in the field of healthcare such as recreating highly complex pathways, DNA sequences, and natural biological systems. In synthetic biology market, genetically modified organisms is the new approach for researchers. However, currently only one engineered gene has been developed, with increasing focus on creating clusters of genes. Also, due to the rising demand for vaccines in high income countries, synthetic biologists are more inclined towards research of various types of vaccines that can be used as prophylaxis. According to WHO, in in 2011, high income countries such as the U.S., Japan, and the U.K. contributed around 80% of global vaccine sales revenue, with these regions accounting for 20% volume share.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/112

Synthetic biology market taxonomy:

By Product Type

• Synthetic DNA
• Synthetic cells
• Synthetic genes
• Chassis organisms
• Genetically modified organisms
• Oligonucleotide Synthesis

By Tool

• Xeno-nucleic Acids (XNA)
• Cloning and Assembly kits
• Oligonucleotides
• Enzymes

By Technology

• Enabling Technologies
  • Bioinformatics
  • Site-saturation Mutagenesis
  • Measurement and Modeling
  • Microfluidics
  • Cloning and Sequencing
  • Gene Synthesis
  • Genome Engineering
  • Nanotechnology
• Enabled Technologies
  • Pathway Engineering
  • Next-generation Sequencing

By Application

• Environmental Application
  • Bioremediation
  • Whole-cell Biosensors
• Industrial Application
  • Biofuels and Renewable Energy
  • Industrial Enzymes
  • Biomaterials and Green Chemicals
• Medical Application
  • Artificial Tissue and Tissue Regeneration
  • Pharmaceuticals
  • Drug Discovery and Therapeutics

Request for an in-depth table of contents for this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/112

Government funding supporting synthetic biology market growth:

Growing demand for synthetic biology products such as synthetic DNA, synthetic genes for treatment of diseases and for developing genetic modified products such as hybrid crop, genetically modified animals for enhancing the nutritional value of the food is also contributing towards the growth of the synthetic biology market. Also, various governments are investing in research and development of novel synthetic biology products. For instance, according to the report from U.S. Trends in Synthetic Biology Research at the Wilson Center, during the period of six years from 2008 to 2014, the U.S. invested around US$ 820 million in research for products in synthetic biology. Among different funding agencies, the defense department became a key funder of synthetic biology research dominating the funds by national science foundation. The above key fact also suggests that U.S. is expected to be a significant contributor in synthetic biology market.

Regional analysis of synthetic biology market:

Developed countries such as the U.S., Germany, U.K., France, and Japan have mature markets for synthetic biology mainly due to large funding and favorable government regulation regarding the approval of synthetic biology products. According to genetic engineering & biotechnology news in 2010, the government of three European countries namely the Netherlands, U.K., and Germany invested around US$ 160 million in a span of five years between 2005 and 2010. Regulations such as Toxic Substances Control Act (TSCA) in 1997, cover commercial uses of new microorganisms not regulated by other agencies: primary rules covering industrial biotechnology. European Commission and research agencies have also increased their funding for research in synthetic biology. In emerging economies in Asia-Pacific, Middle East, and Africa, governments are focusing on tackling major issues such as under-nutrition by encouraging adoption of GMO crops. For example, Indian government is had put efforts in the past regarding in terms of intervention programs to combat malnutrition such as Integrated child development services and mid-day meal program This creates a highly conducive environment for market growth.

Additional Information on such Research Findings can be Availed At: https://www.coherentmarketinsights.com/ongoing-insight/synthetic-biology-market-112

Major acquisitions to support the growth in synthetic biology market

There are few recent acquisitions by the big brands in biotechnology that is expected to favor the market for synthetic biology. QIAGEN N.V acquired OmicSoft—a software solutions company that offers scientists and researchers tools to efficiently analyze and visualize the data in bioinformatics. This acquisition is further expected to favor the working efficiency of the company.  Key players operating in the synthetic biology market include DuPont, Amyris, Inc., GenScript USA Inc., Integrated DNA Technologies, Intrexon Corporation, New England Biolabs, Inc., Thermo Fisher Scientific, Inc., Synthetic Genomics, Inc., Royal DSM, and Novozymes.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Bispecific Antibodies Market by Product type, Application, End user, Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a technologically advanced solution for dual targeting strategies within same molecule.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/19

Due to its dual specificity, bispecific antibody can aid in redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.  Catumaxomab and blinatumomab are the two U.S. FDA approved bispecific antibody products, which would fuel growth of the bispecific antibodies market. Bispecific antibodies can be divided into three main classes namely, fragment, symmetric, and asymmetric antibodies. Fragment bispecific antibodies such as a nanobody DART and BiTE are currently undergoing clinical trials. Likewise, tetravalent BsAb - DVD and DAF symmetric antibodies are under research. Companies such as Sanofi S.A., Merck & Co., Inc. and Genentech, Inc. are conducting research on symmetric bispecific antibodies. BEAT, duobody, and crossmab are examples of asymmetric bispecific antibodies, which are currently being researched by Glenmark Pharmaceuticals, Eli Lilly and Company, and Genmab A/S.

Catumaxomab – the first Bispecific antibody boost growth of the bispecific antibodies market

As of 2015, over 60 different BsAb formats have been developed, with some making their way into the clinical trials. Bispecific antibodies market growth is increasing due to the limitation of monoclonal antibodies in drug resistance and failure to respond in treatment. Hence, the bispecific antibodies market is projected to gain significant growth traction in the near future.

Request for an in-depth table of contents for this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/19

Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat malignant ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was approved in Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand name Removab, Catumaxomab is administered to patients with EpCAM-poisitve carcinoma.

North America and Europe are major regions for Bispecific antibodies market

In Europe and North America, incidence of diseases such as lung cancer, cervical cancer, breast cancer, and prostate cancer is increasing, with the regions accounting for the highest incidence rate for these diseases worldwide. Moreover, with these regions being home to major players, these are the largest bispecific antibodies market. Supportive government initiatives are further fueling growth of bispecific antibody treatment markets in North America and Europe.  Increasing healthcare access and awareness in developing regions such as Asia Pacific, Latin America, and Middle East are projected to propel demand for BsAb owing to fuel growth of the bispecific antibodies market in the near future.

Increasing investments to harness the potential of highly effective BsAb Drug Therapy

Various pharmaceutical companies are actively involved in development and manufacture of bispecific antibodies. MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government funding is projected to further encourage research and development in this field.

Additional Information on such Research Findings can be Availed At: https://www.coherentmarketinsights.com/ongoing-insight/bispecific-antibodies-market-19

Key players involved in the Bispecific antibodies market include

Some of the key players in Bispecific antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Healthcare Revenue Cycle Management Market - Global Industry Analysis, Growth, Trends and Forecast to 2024

Revenue cycle management or RCM is a combination of revenue generation, payment, and claims processing. In layman’s terms, it is a healthcare system’s financial system. Its components include all clinical and administrative functions that consist of the management, collection, and capture of revenue gained from patient service. It is primarily the entire lifespan of a patient account in a healthcare organization. Revenue cycle management incorporates the use of specific technological tools to track claims throughout patient’s lifecycle, ensuring that the payments are collected without any hurdle, and claims are addressed successfully. RCM tools let healthcare providers do the billing and identify issues quickly, thereby allowing for the secure stream of revenue. A system that runs efficiently thwarts rejection of claims and preserves an efficient and transparent billing process. Revenue cycle management also includes everything from deciding on patient’s insurance adequacy and eligibility to regulating claims through ICD-10.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/157

HRCM or healthcare revenue cycle management is an important architecture in a healthcare infrastructure. Healthcare organizations employ EHR or Electronic Health Records and computerized performance management to save costs related to the maintenance of their books. This is achieved by lessening the total number of claims denied and by facilitating individuals for adopting online payment platforms. The advent of superior automated elucidations has assisted front desk and clinical staffs, coders & billers, and providers to boost their performance levels in addition to saving time. With the growing business, patients are adopting more than a few payment gateways to make their payments against the services received at hospitals or clinics. Multiple advantages will propel the growth of healthcare revenue cycle management market in the near future.

Integrated solutions is likely to be the primary growth segment in the healthcare revenue cycle management market owing to improved operational competences and smooth economic and clinical structure with better management of treatments, outcomes and most importantly, costs related to these treatments.

Healthcare Revenue Cycle Management Market Taxonomy

On the basis of deployment, the global healthcare RCM market is classified into:

• On-Premise
• Cloud-Based
• Web-Based
• Others

On the basis of component, the global healthcare RCM market is classified into:

• Software
• Services

On the basis of product type, the global healthcare RCM market is classified into:

• Standalone
• Integrated
• Others

On the basis of end user, the global healthcare RCM market is classified into:

• Hospitals
• Laboratories
• Physicians
• Others

Among deployment types, the cloud based solutions holds the majority share in the healthcare revenue cycle management market. The primary factor for the dominance of this segment is high rate of adoption of electronic medium for maintaining health records, thereby ensuring well-organized data mining, superior accessibility of the data and precise evaluation of the data corresponding to health information. This in turn will fuel the growth of the overall healthcare revenue cycle management market.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/healthcare-revenue-cycle-management-market-157

Rising incidences of hospitalizations will drive the overall healthcare revenue cycle management market

According to the American Hospital Association, the total number of registered hospitals in the U.S. was 5,564 in 2015. Moreover, it states that in 2015, the total number of admissions in these hospitals was 35,061,292, i.e. around 35 million patients. Increasing number of hospitalizations, in turn fuels growth of the global healthcare revenue cycle management systems market. Maintaining well organized records of patients is the need of the hour. Additionally, the emerging economies, especially countries such as China and India are likely to show significant growth prospects over the course of the forecast period. Increasing spends on healthcare, availability and accessibility of better healthcare facilities, increasing incidence of diseases and the rising importance of studying historical patient profile across the healthcare industry will augment the overall growth of the market. Government initiates and strict regulatory framework will shape the future of the global healthcare revenue cycle management market.

Major manufacturers in the market compete on the basis of price, and technology (ease of use). Some of the major players operating in the healthcare revenue cycle management market are GE Healthcare, Experian PLC., Eclinicalworks, LLC, Mckesson Corporation, Cerner Corporation, Gebbs Healthcare Solutions, Conifer Health Solutions, LLC. Epic Systems Corporation, Quest Diagnostics Incorporated, Allscripts Healthcare Solutions, Inc., and Athenahealth, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Healthcare Biometrics Market to Surpass US$ 8.7 Billion by 2024: Coherent Market Insights

The Global Healthcare Biometrics Market was valued at US$ 1,333.1 million in 2015 and is projected to expand at a CAGR of 23.4% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Growing security concerns and integration of information technology (IT) with healthcare processes is expected to drive growth of the global healthcare biometrics market.

To know about the assumptions considered for the study, Download the PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/155

Frauds and operational inefficiencies are overriding healthcare administration concerns and needs to be addressed soon for overall profitability and improved efficiency. Use of biometrics ensures safety and controlled access. Healthcare insurers are inundated with fraudulent claims. According to the Coalition against Insurance Fraud—an anti-fraud watchdog group—nearly US$ 80 billion is lost annually in Medicare fraud in the U.S. Besides, giving every patient a digital identity is being increasingly adopted as a practice in hospitals to ease processing at every functional level. Healthcare companies and organizations are actively integrating healthcare IT to aid cost reduction, secure patient information and allow for only authorized access.

Use of mHealth, and electronic health record is increasing rapidly globally. With the use of digital platforms, data security becomes critical as underlines by the Health Insurance Portability and Accountability Act (HIPAA) of 1996. These factors would augment growth of healthcare biometrics market at a rapid rate. Use of fingerprint biometric technology is high, owing to its ease of operation. Moreover, it is a primary biometric technology and is also used by mobile device manufacturers. Use of biometric also finds benefits in providing access to functional departments and documents.

Deployment of biometric systems in healthcare sector is high in developed economies of North America and Europe to ensure effective fraud prevention and securing patent data, especially for those enrolled in clinical trials. Increasing instance of insurance fraud and growing demand for enhanced security of patient data is expected to create a highly conducive environment for growth of the market in the foreseeable future. Celerion—a clinical research service provider—has implemented fingerprint biometric technology in early 2017 to ensure that participants are not enrolled in more than one clinical study at a time. Biometric access control specialist, ievo Ltd, based in the U.K., partnered with Keytracker Ltd. (also based in the U.K.) in February 2017, to offer restricted key access system to the healthcare and construction industries. The fingerprint based technology is intended to provide access to drug storage area only to the authorized personnel.  Such collaborations are imperative in global healthcare biometrics market for market expansion.

To know the latest trends and insights prevalent in the healthcare biometrics market, click the link below: https://www.coherentmarketinsights.com/market-insight/healthcare-biometrics-market-155

Key takeaways of the healthcare biometrics market:

• The global healthcare biometrics market is expected to expand at a CAGR of 23.4% during the forecast period (2016–2024) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
• The fingerprint technology dominates the market in the technology segment as it is the primary biometric technology developed and focused by mobile health device manufacturers
• Different screening technologies such as iris, and vein recognition are expected to gain traction with growing awareness and increasing application areas
• Hospitals and healthcare institutions are the major end users of biometric systems as these organizations deal with a huge database and many functional departments to be accessed securely
• Some of the major players involved in global healthcare biometrics market include BIO-key International, Fujitsu Limited, MorphoTrust, 3M Cogent, Inc., Imprivata, Inc., Crossmatch Technologies, Inc., NEC Corporation, Hitachi Ltd., Integrated Biometrics, and Qualcomm Technologies, Inc.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Gynecological Devices Market to Surpass US$ 4.5 Billion by 2024: Coherent Market Insights

The Global Gynecological Devices Market was valued at US$ 2,667.8 million in 2015 and is projected to expand at a CAGR of 6.3% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Increasing incidence of gynecological disorders is projected to favor the growth for gynecological devices market in the near future.

Additional Information on such Research Findings can be Availed At: https://www.coherentmarketinsights.com/insight/request-sample/152

Around 10% of the global female population is affected by endometriosis according to the estimates by Endmoetriosis UK (2016). Risk of gynecological disorders increases with age. According to the World Bank, female population aged 65 years and above increased exponentially from 6.8% in 2010 to 8.2% in 2015. Furthermore, changing lifestyle habits and risk of infection is expected to result in high incidence of gynecological disorders. The outlook for the gynecological devices market is therefore bright in the foreseeable future.

Safety is one of the major concerns of healthcare practitioners using gynecological devices. Bayer’s Essure is an intra-uterine device (IUD) that has been linked with skin rashes and pelvic pain in women (in the U.S.) who have inserted it as a permanent contraceptive solution. This has led women to remove the Essure through surgery. The U.S. FDA has called for a black box warning for the device. Furthermore, the FDA has also asked manufacturers of power morcellators to mention a warning that the product ‘has not been proved to reduce the risk of spreading cancer’. Power morcellators are used to dissect and remove uterus or uterine fibroids through small incisions. However, these devices are reported to cause uterine cancer, which remain undetected owing to lack of awareness.

Post-surgical complications are among the most frequent complications in abdominopelvic surgery. Endometriosis and infection in pelvic region can stimulate the formation of adhesions, which may lead to discomfort, chronic pain and infertility. Actamax Surgical Materials LLC (subsidiary of DSM Biomedical), submitted an Investigational Device Exemption (IDE) to the U.S. FDA in February 2017 for its Actamax adhesion barrier to be utilized in in gynecological laparoscopic surgery. Such innovative solutions for the existing concerns on the gynecological surgeries would favor the growth of gynecological devices market globally.

To know the latest trends and insights prevalent in the gynecological devices market, click the link below: https://www.coherentmarketinsights.com/market-insight/gynecological-devices-market-152

Being a very intimate category of devices, safety is therefore the priority for users. Manufacturers need to gather enough evidences of safety and efficacy to avoid post-marketing recalls and regulatory hurdles. Specialized speculums, curettes, and forceps ease the surgical procedures. Demand for gynecological chairs is expected to grow rapidly during the forecast period as hospitals upgrade their infrastructure, especially in emerging economies such as India, China, and Brazil.

Key takeaways of the market:

·         The global gynecological devices market is expected to expand at a CAGR of 6.3% during the forecast period (2016–2024). Rise in number of gynecological surgeries is expected to favor the growth of gynecological devices market in the near future.

·         Surgical devices is expected to dominate the market throughout the forecast period as these devices are in regular demand for gynecological surgeries

·         Demand for gynecological chairs is projected to grow gradually with growing investment in infrastructure upgradation and establishment of new surgical and gynecological examination rooms

·         Gynecological devices market in the Asia Pacific region would be growing rapidly with increasing incidence of gynecological disorders and the number of gynecological surgeries

·         Hospital are the major users of gynecological devices and would be driving the global gynecological devices market

·         Major market payers including Ethicon, Inc., Hologic, Inc., Stryker Corporation, Cooper Surgical, Inc., Karl Storz GmbH& Co. KG, Boston Scientific Corporation, and Richard Wolf GmbH need to consider the safety of deices to avoid any post-marketing issues

·         These players can opt for emerging nations for a rapid growth in business expansion

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights
1001 4th Ave, 

#3200                   

Seattle, WA 98154

Tel:  +1-206-701-6702

Email: sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com/

Visit Blog : http://globalresearchtrends.blogspot.in/

Anti-Suicide Drugs Market to Surpass US$ 4.8 Billion by 2024: Coherent Market Insights

The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Introduction of novel approved drugs, expected to be commercialized post-2020, intended for treatment of suicidal ideation would be a major breakthrough for the global anti-suicide drugs market.

Fill the form for an exclusive sample of this report@ https://www.coherentmarketinsights.com/insight/request-sample/10

Until recently, suicidal ideation has been treated with anti-depressants, anti-anxiety, and anti-psychotic drugs. The trend would continue until the expected launch of Cyclurad by NeruoRx Pharma during the latter half of the forecast period (2016–2024). Cyclurad is a combination of D-cycloserine and Lurasidone and indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. Other drug candidates are also in the pipeline, intended for treatment of suicidal ideation in major depressive disorder (MDD).

Suicide is among the major economic burdens to the global economy. According to the World Health Organization (WHO), over 800,000 people commit suicide every year. Most of the suicidal deaths occur in Asia, Africa, and Eastern Europe. Moreover, many suicidal attempts go unnoticed until and seldom are reported to suicidal prevention organizations, who can help alleviate the issue. Stop Suicide, Yellow Ribbon Suicide Prevention Program, and American Foundation for Suicide Prevention are some of the leading organizations working for preventing suicides. High prevalence of suicidal attempts and deaths would be another stimulus besides the introduction of novel drugs for the growth of anti-suicide drugs market.

N-Methyl-D-aspartate receptor (NMDAR) agonists and antagonist are the prospective candidate for treating suicidal ideation. Companies banking on anti-depressants and anti-psychotic drugs for treating patients at risk for suicide should reconsider their strategy, considering these are not very effective at addressing the issue. Nonetheless, these drug class are not approved for use in treating patients at risk for suicide. The global anti-suicide drugs market has been driven majorly by off-label recommendations and prescriptions of anti-depressants, anti-anxiety and anti-psychotic drugs.

Inadequate reach of healthcare facilities and affordable medications is hindering growth of overall healthcare market in emerging economies such as India, China, Brazil, and Indonesia. Therefore, companies introducing novel anti-suicidal drugs would be facing a challenge in market penetration in these nations and would be able to capture only a part of these markets to capitalize on the lucrative growth opportunities in these regions. North America and Europe remain potential markets at initial stages for the anti-suicidal drugs. High suicidal rates and accessibility to better medical therapies would be the major contributing factors for the anti-suicide drugs market in these regions.

To know the latest trends and insights prevalent in the anti-suicide drugs market, click the link below: https://www.coherentmarketinsights.com/market-insight/anti-suicide-drugs-market-10

Key takeaways of the market:

• The global anti-suicide drugs market is majorly characterized by the use of anti-depressants, anti-anxiety and anti-psychotic drugs
• The global anti-suicide drugs market is expected to expand at a CAGR of 4.2% during the forecast period (2016–2024). Rising incidence of suicides across the globe is expected to favor the market growth for anti-suicide drugs over the forecast period.

Get This Report Now: http://bit.ly/2mCqg3M

• Suicidal rates are higher in Asia, Eastern Europe and Africa regions
• The antibiotic analog (NMDA agonist) segment in the global anti-suicide drugs market is estimated to be growing faster post its FDA approval and commercialization
• Market growth for anti-depressants and anti-anxiety drugs is projected to be impacted negatively by the launch of FDA approved anti-suicidal drugs expected towards the latter-half of the forecast period
• Some of the major players present in the global anti-suicide drugs market are Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, 

#3200                   

Seattle, WA 98154

Tel:  +1-206-701-6702

Email: sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com/

Visit Blog : http://globalresearchtrends.blogspot.in/

Digital Radiography Market to Surpass US$ 12.5 Billion by 2024 : Coherent Market Insights

The Global Digital Radiography Market was valued at US$ 7,538.8 million in 2015 and is projected to expand at a CAGR of 5.9% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Increase in demand for high quality imaging in the healthcare sector is projected to favor the market for digital radiography market in the near future.

Additional Information on such Research Findings can be Availed At: https://www.coherentmarketinsights.com/insight/request-sample/151

The healthcare sector has witnessed advancements under clinical practices such as introduction of novel digital detector technologies and radiographic techniques. There are various technical factors that are responsible for adoption of new radiography techniques. Differences between the older analogical technique and digital technique do not stop at just high image quality associated with the latter, but also the lower exposure time and strength of the X-ray on the patient. Digital radiography allows for over- exposure that produces better quality images. The steady growth in global economy and the rise in healthcare awareness are propelling the medical devices industry to achieve significant growth in terms of revenue, which in turn is projected to support the digital radiography market over the forecast period. Also, various new acquisitions and investments along with novel product launches are expected to favor growth of the digital x-ray market in the near future. In 2015, Konica Minolta – a primary imaging solution company – introduced a new radiography solution named AeroDR XE – this is expected to provide a lower weight version to deliver Primary Imaging at the point-of-care.

Due to significant shifts in the delivery of care, reimbursement scenario and health system management and other healthcare organizations strategies are expected to favor growth of the digital radiography market. The digital radiography technique is now extending into non-clinical areas of non-destructive testing. However, there are few factors such as requirement of skilled and trained radiologists for operating novel techniques and the change in work patterns of the machine that can hinder market growth over the forecast period. Although, the global market has been struck by the moderate economic meltdown, the market for medical devices is experiencing constant growth. Furthermore, primary factors such as modernization and technical advancements are projected to favor growth of the digital radiography market over the forecast period.

The market for digital radiography is expected to grow steadily over the forecast period. Since digital radiography plays an important role in providing vital imaging services in the healthcare sector, varying with different requirement of variations in the type of patient site. The rise in number of road accidents and casualties are favoring growth in demand for digital x-rays in the radiography market. Also, the need for specific treatment and rise in awareness among the population regarding various healthcare techniques are propelling demand for better quality results, which in turn is expected to favor the radiography market in the near future. Furthermore, the rise in population of elderly population around the globe is expected to positively favor the digital radiography market, as they are more prone to injuries and are highly susceptible to skeletal disorders. According to National Institute on Aging, in 2016, around 8.5% of the population was above the age of 65, which creates a highly conducive environment for growth of the digital x-ray market.

To know the latest trends and insights prevalent in the digital radiography market, click the link below: https://www.coherentmarketinsights.com/market-insight/digital-radiography-market-151

Key takeaways of the market:

• The global digital radiography market is expected to expand at a CAGR of 5.9% during the forecast period (2016–2024). The modest growth rate of the market is attributed to steadily growing adoption of digital radiography systems.
• Adoption of digital radiography systems is expected to be more rapid in the emerging nations such as India, China, Brazil, Israel, and Indonesia
• Convenience in imaging would be a major driving factor for mobile digital radiography systems with rapid adoption projected in emerging nations
• Requirement of skilled labor would be prevailing throughout the forecast period which indirectly impacts the adoption of new digital radiography systems and the growth of global digital radiography market
• The global digital radiography market is characterized by strategic research and development and advancement in the products in the imaging market with portability options and strategic collaborations of the various organizations in the radiography market.
• Some of the major players are 3DX-RAY, ANRITSU INFIVIS, Bosello High Technology, COMET, GE Healthcare, Mettler-Toledo International, Nikon, North Star Imaging, VJ Technologies, Fujifilm Holdings, Philips Healthcare, Shimadzu Corporation, Toshiba Medical System Corporation, Carestream Health.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.